BOSTON, June 22, 2023 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced it ...
Haemonetics describes its machines as the most popular devices used at plasma collection centers, the facilities where donors are paid to give plasma. CSL Plasma, the largest of those plasma ...
Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently.
Haemonetics Corporation reported strong fiscal Q1 2024 financial performance, beating estimates for non-GAAP EPS and revenue. The company's advancements in the NexSys Plasma collection system and ...
Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback